Skip to content

SG&A at other companies

Eli Lilly logo
Eli LillyLLY
$2.93B+18.9%
Cardinal Health logo
Cardinal HealthCAH
$1.54B+17.3%
McKesson logo
McKessonMCK
$1.8B-9.1%
CryoPort, Inc. logo
CryoPort, Inc.CYRX
$27.62M+26.1%
AbbVie logo
AbbVieABBV
$3.58B+8.7%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$138.86M+17.4%

Other financials

Income statement

See full
Revenue$78.4B+3.8%
Gross profit$3.6B+17.3%
Operating income$1.1B+10.3%
Net income$1.6B+129%
EPS (diluted)$8.40+128%

Balance sheet

See full
Cash & equivalents$2.2B+10.0%
Total debt$12.2B+71.9%
Total equity$3.4B+235%
Total assets$81.7B+14.7%

Cash flow

See full
Operating cash flow-$2.3B+15.2%
CapEx$165.6M+28.3%
Free cash flow-$2.4B+14.2%

Valuation

See full
Market cap$55.83B-1.9%
Enterprise value$65.84B+6.1%
P/E15.5×+3.1×
P/S0.2×0.0×

Profitability

See full
Gross margin3.8%+0.4pp
Operating margin0.8%0.0pp
Net margin0.6%-0.1pp
FCF margin1.1%+1.0pp

Returns & leverage

See full
Return on equity130.6%-99.8pp
Debt / equity3.6×-3.4×
Current ratio0.9×+0.1×

Where this comes from

Reported directly by Cencora in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Cencora’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cencora's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cencora's SG&A?
Cencora (COR) reported SG&A of $1.98B in Q1 2026.
How has Cencora's SG&A changed year-over-year?
Cencora's SG&A increased by 23.6% year-over-year, from $1.6B to $1.98B.
What is the long-term trend for Cencora's SG&A?
Over 4 years (2021 to 2025), Cencora's SG&A has grown at a 15.9% compound annual growth rate (CAGR), from $3.59B to $6.49B.
What does SG&A mean?
Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.